CD7 CAR-T: a bridge to transplant in AML

被引：0
|
作者：
Mamonkin, Maksim [1 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
来源：
BLOOD | 2025年 / 145卷 / 10期
关键词：
THERAPY; 1ST-IN-HUMAN; CELLS;
D O I：
10.1182/blood.2024027442
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Lu et al1 report early results from a phase 1 study of autologous CD7 chimeric antigen receptor-modified T cells (CD7 CAR-T) in patients with acute myeloid leukemia (AML). The authors describe the safety and preliminary efficacy of CD7 CAR-T, which induced disease remission in most patients. However, the responses were durable only in those who received subsequent allogeneic hematopoietic stem cell transplant (alloHSCT).
引用
收藏
页码：995 / 996
页数：2
相关论文
共 50 条
  • [31] Biomarkers as targets for CAR-T/NK cell therapy in AML
    Shao, Ruonan
    Li, Zijian
    Xin, Honglei
    Jiang, Suyu
    Zhu, Yilin
    Liu, Jingan
    Huang, Rong
    Xu, Kailin
    Shi, Xiaofeng
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [32] In Vivo Generation of Both CAR T Cells and CAR NK Cells Using a CD7 Targeted Lentiviral Vector
    Mullen, Karla F.
    Grubaugh, Daniel
    Welsh, Kayla R.
    Foss, Jeffery
    Nguyen, Julia L. A.
    Gheewala, Nishi
    Kuri-Cervantes, Leticia
    Andorko, James I.
    Schnepp, Bruce C.
    Culp, Timothy D.
    Johnson, Philip R.
    MOLECULAR THERAPY, 2024, 32 (04) : 1 - 2
  • [33] CAR-T treatment of pediatric AML: a long and winding road
    De Moerloose, Barbara
    BLOOD, 2021, 137 (08) : 1004 - 1006
  • [34] Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment
    Ma, Yun-Ju
    Dai, Hai-Ping
    Cui, Qing-Ya
    Cui, Wei
    Zhu, Wen-Juan
    Qu, Chang-Ju
    Kang, Li-Qing
    Zhu, Ming-Qing
    Zhu, Xia-Ming
    Liu, Dan-Dan
    Feng, Yu-Feng
    Shen, Hong-Jie
    Liu, Tian-Hui
    Qiu, Hui-Ying
    Yu, Lei
    Wu, De-Pei
    Tang, Xiao-Wen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (02): : 615 - +
  • [35] THE MRD STATUS ON DAY 7 AND CD4 COUNT AT 1 MONTH AFTER CAR-T THERAPY ARE PROGNOSTIC INDICATORS IN CAR-T TREATMENTS
    Gao, Li
    Lu, Jun
    Cheng, Shengqin
    Wang, Yuxuan
    Xiao, Peifang
    He, Hailong
    Wang, Yi
    Li, Jie
    Hu, Shaoyan
    BONE MARROW TRANSPLANTATION, 2024, 59 : 14 - 14
  • [36] Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
    Hu, Yongxian
    Zhang, Mingming
    Yang, Tingting
    Mo, Zhuomao
    Wei, Guoqing
    Jing, Ruirui
    Zhao, Houli
    Chen, Rongrong
    Zu, Cheng
    Gu, Tianning
    Xiao, Pingnan
    Hong, Ruimin
    Feng, Jingjing
    Fu, Shan
    Kong, Delin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Liang, Bin
    Yuan, Xiaolin
    Cui, Qu
    Guo, Hongshan
    Yu, Yunxian
    Feng, Youqin
    Jin, Chunxiang
    Ren, Jiangtao
    Chang, Alex H.
    Wang, Dongrui
    Huang, He
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (16): : 1467 - 1480
  • [37] Donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.
    Pan, Jing
    Deng, Biping
    Ling, Zhuojun
    Song, Weiliang
    Xu, Jinlong
    Duan, Jiajia
    Wang, Zelin
    Chang, Alex
    Feng, Xiaoming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
    Su, Lihe
    Wu, Lan
    Lobb, Roy R.
    Rennert, Paul D.
    Ambrose, Christine
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [39] CAR-T ENGAGER PROTEINS OPTIMIZE ANTI-CD19 CAR-T CELL THERAPIES FOR LYMPHOMA
    Rennert, Paul
    Su, Lihe
    Wu, Lan
    Lobb, Roy
    Ambrose, Christine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A187 - A187
  • [40] CD7 CAR T bridging to allo-HSCT in R/R T-ALL: A case report
    Meng Fanqiao
    Chen, Xiuqiong
    Ren, Xiaotong
    Li, Lijuan
    PEDIATRIC TRANSPLANTATION, 2024, 28 (03)
12345